Shares of the company have plunged more than 90 percent from the stock’s high of $257 in July 2015. The sale of Canada-based Valeant’s skincare …
Valeant stock
Investors in Dendreon Corp (NASD: DNDN) saw new options begin trading today, for the November 1st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DNDN options …
Sold Dendreon Pharmaceuticals to the Sanpower Group Co. for $820 ... announced today that it has commenced an underwritten public offering of 4,000,000 shares of its common stock. The Company expects …
The stock had plunged more than 90% since August 2015 amid intense ... AcneFree and Ambi — from Valeant for about $1.3 billion in cash, while …
CFO7d
Valeant
The announcement so far has failed to move the needle on the troubled Bausch & Lomb parent’s lagging stock price. The Quebec-based firm ... USA Inc. for $1.3 billion and the sale of its stake in Dendreon
Bausch Lomb
Dendreon Corporation (DNDN) stock is down about 64% during premarket trade today, after the company announced it had reached an agreement with bondholders for a financial restructure and filed for Chapter 11 …
The stock has a 50 day moving average of $15.19 and a 200-day moving average of $21.74. Its recent success in the sales deal of Dendreon, as well as its skincare units, have helped it raise over $2 billion and make debt …
Valeant Pharmaceuticals Intl
TORONTO - The Toronto stock market eked out a moderate gain amid two major ... It will also sell its interest in Dendreon Pharmaceuticals to a privately owned Chinese conglomerate, Sanpower Group, for US$819.9 …
Gildan deals
The Seattle-based biotech company (NASDAQ: DNDN) saw its stock plummet about 60 percent in after-hours trading today after it issued a surprisingly bad second-quarter financial report. The loss, if it holds up in …
Sales